REFERENCES
- Kessler RC, McGonagle KA, Zhao S et al (1994) Lifetime and 12- month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 51: 8–19.
- Sartorius N, U¨ stu¨ n B, Lecrubier Y, Wittchen H-U (1996) Depression comorbid with anxiety: results from the WHO study on psychological disorders in primary health care. Br J Psychiatry 168: 38–43.
- Thompson C, Kinmonth AL, Stevens L et al (2000) Effects of a clinical-practice guideline and practice-based education on detection and outcome of depression in primary care: Hampshire Depression Project randomised controlled trial. Lancet 355: 185–91.
- Wittchen HU, Zhaos S, Kessler RC, Eaton WW (1994) DSM-III-R generalised anxiety disorder in the National Comorbidity Survey. Arch Gen Psychiatry 51: 355–64.
- Davidson JR, Hughes DL, George LK, Blazer DG (1993) The epidemiology of social phobia: findings from the Duke Epidemiological Catchment Area Study. Psychol Med 23: 709–18.
- Magee WJ, Eaton WW, Wittchen HU et al (1996) Agoraphobia, simple phobia, and social phobia in the National Comorbidity Survey. Arch Gen Psychiatry 53: 159–68.
- Patel A, Knapp M, Henderson J, Baldwin D (2002) The economic consequences of social phobia. J Affect Disord 68: 221–33.
- Issac M (1999) Where are we going with SSRIs? Eur Neuropsychopharmacol 9 (Suppl 3): S101–6.
- Montgomery SA, Loft H, Sa´ nchez C et al (2001) Escitalopram (S- enantiomer of citalopram): clinical efficacy and onset of action predicted from a rat model. Pharmacol Toxicol 88: 282–6.
- Burke WJ, Gergel I, Bose A (2002) Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry 63: 331–6.
- Wade AG, Lemming O, Hedegaard K (2002) Escitalopram 10 mg/ day is effective and well-tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 17: 95–102.
- Lepola UM, Loft H, Reines EH (2003) Escitalopram (10 -20 mg/ day) is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 18: 211–7.
- Stahl S, Gergel I, Li D (2003) Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 64: 1322–7.
- Kasper S, Loft H, Nil R (2002) Escitalopram is efficacious and well tolerated in the treatment of social anxiety disorder. Nordic J Psych 56: 108.
- Lader M, Stender K, Bu¨ rger V, Nil R (2004) The efficacy and tolerability of escitalopram in the short- and long-term treatment of social anxiety disorder: a randomised, double-blind, placebo- controlled, fixed-dose study. Depr Anxiety 19: 241–8.
- Montgomery SA, Du¨ rr-Pal N, Loft H, Nil R (2003) Relapse prevention by escitalopram treatment of patients with social anxiety disorder (SAD). Eur Neuropsychopharmacol 13 (Suppl 4): S364.
- Davidson J, Bose A, Su G (2002) Escitalopram in the treatment of generalized anxiety disorder. Int J Neuropsychopharmacol 5 (Suppl 1): S214.
- Davidson JRT, Bose A, Korotzer A, Zheng H (2004) Escitalopram in the treatment of generalized anxiety disorder: a double-blind, placebo controlled, flexible dose study. Depr Anxiety 19: 234–40.